Entries are now open for the 2024 ABPCO Excellence Awards, recognizing the resilience and innovation of professionals in the conference and events industry. Submit by July 31, 2024.
Tom Nolan reviews this week’s research
Over the past year we’ve seen various trials that assess vaping as an intervention for smoking cessation. Now we have smoking cessation drugs being studied as interventions to help people stop vaping. Cytisinicline, a plant based alkaloid that targets nicotinic acetylcholine receptors, has been available in the UK since the start of this year. One hundred and sixty non-smokers who use nicotine vapes were randomised to either cytisinicline 3 mg three times a day for 12 weeks or placebo (both groups received behavioural support). Participants were asked to set a quit date seven to 14 days after the start of treatment. Some 31.8% of those in the cytisinicline group, and 15.1% in the placebo group had stopped vaping between nine and 12 weeks (odds ratio, 2.64; 95% CI, 1.06 to 7.10). However, by 16 weeks the gap between the groups had …
Nipocalimab's Unique Mechanism Gets Second Chance in RA medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.